Syntagon to deliver presentation on controlling genotoxic impurities

Aug 21 2009

Leading contract research organisation, Syntagon, is to deliver a presentation on controlling genotoxic impurities at one of the Pharma industry’s highest profile events, CPhI Worldwide, being held this October in Madrid, Spain.

Boasting some 1,430 exhibitors and in excess of 25,000 participants from more than 125 countries, CPhI Worldwide is the largest event in the Pharma industry. This year, CPhI will take place in Madrid and run between October 13 and 15. First held in 1990, when just 16 exhibitors drew 250 visitors, CPhI has grown rapidly to become an event of unrivalled importance for the Pharma industry.

Syntagon’s Technical Director, Dr Anders Högdin, will give a presentation entitled ‘Controlling Potential Genotoxic Impurities for Phase I clinical trials’. The control of potential genotoxic impurities (PGIs) is becoming increasingly high profile and Syntagon has acquired extensive experience in the area.

“We know that controlling and quantifying impurities is a key task during drug development. Of these impurities, (potential) genotoxic impurities are particularly important due their ability to cause genetic damage,” Högdin adds.

The presentation sets out to explore current industry consensus and highlight Syntagon’s experience in this increasingly important area.

“Our expertise in impurity profiling, coupled with a close working relationship between our highly skilled analytical and organic chemists, allows us to excel in the field of PGI control,” says Högdin.

The presentation is due to be held on the second day of CPhI – October 14 – at ‘Speaker’s Corner’ in Hall 8 at 11 AM.